Cargando…
Updated Prognostic Factors in Localized NSCLC
SIMPLE SUMMARY: In resected lung cancer, adjuvant and neoadjuvant chemotherapy following surgery are currently mainly based on TNM classification. With the validation and ongoing trials of targeted therapies in this situation, the relapse risk evaluation needs to be improved to better discriminate p...
Autores principales: | Garinet, Simon, Wang, Pascal, Mansuet-Lupo, Audrey, Fournel, Ludovic, Wislez, Marie, Blons, Hélène |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945995/ https://www.ncbi.nlm.nih.gov/pubmed/35326552 http://dx.doi.org/10.3390/cancers14061400 |
Ejemplares similares
-
Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?
por: Garinet, Simon, et al.
Publicado: (2018) -
Pre-Disease and Pre-Surgery BMI, Weight Loss and Sarcopenia Impact Survival of Resected Lung Cancer Independently of Tumor Stage
por: Icard, Philippe, et al.
Publicado: (2020) -
Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
por: Perrier, Alexandre, et al.
Publicado: (2020) -
Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?
por: Mansuet-Lupo, Audrey, et al.
Publicado: (2014) -
Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study
por: Tiako Meyo, Manuela, et al.
Publicado: (2020)